Joseph joined Turnstone from Scorpion Therapeutics where he was Executive Vice President, General Counsel and Secretary. Joseph serves as Senior Vice President and General Counsel, bringing to Turnstone more than 30 years of experience in mergers and acquisitions, collaborations, and securities offerings and corporate governance. in Pathology from the University of London. in Biomedical Engineering from the University of Strathclyde in Glasgow, and Ph.D.
in Biological Sciences from the University of Edinburgh, M.Sc. His previous roles included Executive Director of Integrative Research and Senior Director of Research at Celgene, where he led technology and cell therapy product scouting, alliance identification and business development activities, initiated engineered T cell programs, and developed novel therapeutic candidates based on hematopoietic stem cells and human placenta-derived cells and Head of the Molecular and Cellular Biology research group for GE Global Research at General Electric. Prior to this, Dr Abbot served as Chief Development Officer at Fate Therapeutics and oversaw development of hematopoietic and induced pluripotent stem cell-based immunotherapeutics. He joined Turnstone from Adicet Bio where he was Chief Scientific and Chief Operating Officer, responsible for R&D activities for allogeneic gamma delta T cell therapies. Abbot has more than 20 years of research and development experience in cell-based products and leads Turnstone’s R&D organization. We are developing next-generation TIL therapies designed to drive therapeutic benefit and curative outcomes across multiple solid tumors.ĭr. We are developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which we refer to as Selected TILs. To address this problem, we are pioneering a differentiated approach to tumor infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. We believe the most significant challenge to creating curative immunotherapies in these patients is the low numbers of T cells that can recognize and attack the tumor, which we refer to as tumor-reactive T cells. Approved immunotherapies represent a significant advancement in the treatment of solid tumors, but many patients either do not respond or experience relapsed disease following an initial response. Solid tumors present a major burden to society, with high mortality and poor outcomes associated with more advanced disease. At Turnstone, our mission is to develop new medicines to treat and cure patients with solid tumors.
0 kommentar(er)
